Status: Recruiting
ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
The purpose of this study is to determine the safety and efficacy of a PEPIDH1M vaccine in combination with vorasidenib, a dual inhibitor of mutant IDH1 and IDH2 enzymes, in adult patients diagnosed with recurrent IDH1 mutant lower grade gliomas.
Participants needed: 48
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Katy Peters, MD, PhDUpdated: Jul 18, 2025Locations: 1
Eligibility criteria
Age ≥ 18 years [+17]
Prior invasive malignancy (except for non-melanomatous skin cancer) unless disea... [+17]